801311-41-1

Upstream product

• 773865-48-8 6-iodo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 801315-31-1 4-chloro-6-iodo-8-methylquinoline-3-carboxamide 
• 951006-38-5 diethyl 2-(((4-iodo-2-methylphenyl)amino)methylene)malonate 
• 951006-39-6 ethyl 6-iodo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 13194-68-8 4-iodo-2-methylaniline 
• 801316-10-9 methyl 3-(3-carbamoyl-4-(3-methoxyphenylamino)-8-methylquinolin-6-ylthio)benzoate 
• 807325-83-3 6-iodo-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide 
• 801311-24-0 methyl 3-[[3-carbamoyl-4-[(3-methoxyphenyl)amino]-8-methylquinolin-6-yl]sulfonyl]benzoate 

Downstream Products

• 1346655-58-0 4-((3-methoxyphenyl)amino)-8-methyl-6-((3-(4-oxopiperidine-1-carbonyl)phenyl)sulfonyl)quinoline-3-carboxamide 

Relevant academic research and scientific papers

Repurposing human PDE4 inhibitors for neglected tropical diseases. evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of pdeb1 of trypanosoma brucei

Cyclic nucleotide phosphodiesterases (PDEs) have been identified as important enzyme targets for drug development in both humans and Trypanosoma brucei, the causative agent of human African trypanosomiasis. With this in mind, we recently reported the prof

QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS

There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.